Full course description
Description
This training provides an in-depth review of the latest advancements in antiretroviral therapy (ART) as presented at CROI 2023. Participants will explore key clinical trials, emerging treatment strategies, and updates on long-acting ART options. The session covers findings related to weight changes with ART regimens, cardiovascular risks, and innovative treatment approaches for virologically suppressed and viremic patients.
Target Audience
Healthcare professionals, HIV specialists, researchers, policymakers, and public health practitioners involved in HIV/AIDS treatment and management.
Learning Outcomes
After completing this training, you will be able to:
- Understand the latest findings on antiretroviral therapy effectiveness and safety from CROI 2023.
- Describe the implications of switching ART regimens on patient outcomes, including weight and cardiovascular risks.
- Assess the role of long-acting injectable ART in maintaining viral suppression, especially in adherence-challenged populations.
- Analyze novel treatment strategies for people experiencing virologic failure, including the use of lenacapavir and second-generation integrase inhibitors.